MX2021001398A - Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico. - Google Patents
Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico.Info
- Publication number
- MX2021001398A MX2021001398A MX2021001398A MX2021001398A MX2021001398A MX 2021001398 A MX2021001398 A MX 2021001398A MX 2021001398 A MX2021001398 A MX 2021001398A MX 2021001398 A MX2021001398 A MX 2021001398A MX 2021001398 A MX2021001398 A MX 2021001398A
- Authority
- MX
- Mexico
- Prior art keywords
- egf
- once
- inhibition
- antibodies
- kinase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001131—Epidermal growth factor [EGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862715351P | 2018-08-07 | 2018-08-07 | |
| US201862727056P | 2018-09-05 | 2018-09-05 | |
| US201862748772P | 2018-10-22 | 2018-10-22 | |
| US201862760529P | 2018-11-13 | 2018-11-13 | |
| US201962822290P | 2019-03-22 | 2019-03-22 | |
| PCT/IB2019/000905 WO2020030977A2 (en) | 2018-08-07 | 2019-08-07 | Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001398A true MX2021001398A (es) | 2021-08-16 |
Family
ID=68425157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001398A MX2021001398A (es) | 2018-08-07 | 2019-08-07 | Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12257245B2 (enExample) |
| EP (1) | EP3833384A2 (enExample) |
| JP (1) | JP2021534094A (enExample) |
| KR (1) | KR20210041571A (enExample) |
| CN (1) | CN112996534B (enExample) |
| AU (1) | AU2019319109A1 (enExample) |
| BR (1) | BR112021002145A2 (enExample) |
| CA (1) | CA3108236A1 (enExample) |
| IL (1) | IL280632A (enExample) |
| MX (1) | MX2021001398A (enExample) |
| WO (1) | WO2020030977A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112300284B (zh) * | 2020-12-29 | 2021-04-06 | 慈达(广州)生物技术有限公司 | 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒 |
| WO2022256360A1 (en) * | 2021-06-02 | 2022-12-08 | Neuvogen, Inc. | Tumor cell vaccines |
| WO2023059801A1 (en) * | 2021-10-06 | 2023-04-13 | The Regents Of The University Of Colorado, A Body Corporate | Biomarkers for egfr-mediated resistance in oncogene-driven cancers and methods of treating, preventing, and/or ameliorating oncogene-driven cancers |
| KR102685187B1 (ko) | 2021-10-15 | 2024-07-16 | 제이투에이치바이오텍 (주) | Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도 |
| MX2024005177A (es) * | 2021-10-28 | 2024-08-27 | In3Bio Ltd | Métodos de uso de anticuerpos anti-fce para aumentar la actividad de los inhibidores de braf y kras. |
| WO2023138576A1 (zh) * | 2022-01-18 | 2023-07-27 | 齐鲁制药有限公司 | 螺环芳基磷氧化物与抗egfr抗体的药物组合 |
| WO2024017352A1 (zh) * | 2022-07-22 | 2024-01-25 | 四川大学 | 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒 |
| WO2024249331A1 (en) * | 2023-05-26 | 2024-12-05 | The Board Of Regents Of The University Of Texas System | Combined rtk and alk inhibition in rtk driven cancers |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPH10147952A (ja) | 1996-11-18 | 1998-06-02 | Komatsu Ltd | ブルドーザのドージング装置 |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| AU2012312515A1 (en) * | 2011-09-19 | 2014-03-13 | Genentech, Inc. | Combination treatments comprising c-met antagonists and B-raf antagonists |
| KR102068374B1 (ko) | 2012-03-06 | 2020-01-20 | 세파론, 인코포레이티드 | 이중 alk 및 fak 억제제로서의 융합된 비시클릭 2,4-디아미노피리미딘 유도체 |
| US20150218652A1 (en) * | 2012-08-31 | 2015-08-06 | The Regents Of The Unversity Of Colorado, A Body Corporate | Methods for diagnosis and treatment of cancer |
| US20160017431A1 (en) * | 2014-03-28 | 2016-01-21 | Driver Group | Methods for Predicting EGFR Tyrosine Kinase Inhibitor Efficacy |
| KR102359214B1 (ko) * | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| US12595297B2 (en) * | 2015-05-12 | 2026-04-07 | In3Bio Ltd. | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors |
| AU2016274585A1 (en) * | 2015-06-08 | 2017-12-14 | Genentech, Inc. | Methods of treating cancer using anti-OX40 antibodies |
| EP3303397A1 (en) * | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
| CA3070034A1 (en) | 2017-07-18 | 2019-01-24 | In3Bio Ltd. | Synthetic proteins and therapeutic uses thereof |
| RU2654695C1 (ru) | 2017-07-28 | 2018-05-22 | Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") | 8-(1-{ 4-{ (5-Хлор-4-{ (2-(диметилфосфорил)фенил)амино} пиримидин-2-ил)амино)-3-метоксифенил} пиперидин-4-ил)-1-метил-1,8-диазаспиро(4.5)декан-2-он и его фармацевтически приемлемые соли в качестве модулятора ALK и EGER, предназначенные для лечения рака |
-
2019
- 2019-08-07 MX MX2021001398A patent/MX2021001398A/es unknown
- 2019-08-07 JP JP2021506465A patent/JP2021534094A/ja active Pending
- 2019-08-07 WO PCT/IB2019/000905 patent/WO2020030977A2/en not_active Ceased
- 2019-08-07 EP EP19797349.8A patent/EP3833384A2/en active Pending
- 2019-08-07 CN CN201980062030.6A patent/CN112996534B/zh active Active
- 2019-08-07 CA CA3108236A patent/CA3108236A1/en active Pending
- 2019-08-07 US US16/534,230 patent/US12257245B2/en active Active
- 2019-08-07 KR KR1020217004498A patent/KR20210041571A/ko not_active Ceased
- 2019-08-07 AU AU2019319109A patent/AU2019319109A1/en not_active Abandoned
- 2019-08-07 BR BR112021002145A patent/BR112021002145A2/pt unknown
-
2021
- 2021-02-02 IL IL280632A patent/IL280632A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3833384A2 (en) | 2021-06-16 |
| US20200046690A1 (en) | 2020-02-13 |
| IL280632A (en) | 2021-03-25 |
| JP2021534094A (ja) | 2021-12-09 |
| AU2019319109A1 (en) | 2021-02-25 |
| BR112021002145A2 (pt) | 2021-12-14 |
| US12257245B2 (en) | 2025-03-25 |
| KR20210041571A (ko) | 2021-04-15 |
| WO2020030977A3 (en) | 2020-06-18 |
| CN112996534A (zh) | 2021-06-18 |
| WO2020030977A2 (en) | 2020-02-13 |
| CA3108236A1 (en) | 2020-02-13 |
| CN112996534B (zh) | 2025-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020030977A3 (en) | Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors | |
| PH12013502333A1 (en) | Method for egfr directed combination treatment of cancer | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| MY200247A (en) | Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors | |
| JP2019517549A5 (enExample) | ||
| MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
| JP2021534094A5 (enExample) | ||
| Mageau et al. | Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: report of four cases | |
| TW202033188A (zh) | 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療 | |
| MX2007004549A (es) | Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico. | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| WO2024112527A3 (en) | Methods for the treatment of thyroid eye disease | |
| WO2022010813A3 (en) | Enhancing immune responses through targeted antigen expression | |
| MX2024006168A (es) | Composicion farmaceutica y uso de la misma. | |
| MX2023013614A (es) | Uso de conjugado farmaco-anticuerpo en combinacion con inhibidor de puntos de control inmunitario en el tratamiento del cancer urotelial. | |
| MX2026001173A (es) | Moduladores del potencial de receptor transitorio melastatina 3 (trpm3) para el tratamiento del dolor | |
| JOP20240049A1 (ar) | سوتوراسيب وجسم مضاد لـ egfr لعلاج سرطان يشمل طفرة kras g12c | |
| MX2024014906A (es) | Administracion subcutanea de onfasprodil y métodos de dosificación para su itilizacion en el tratamiento de trastornos depresivos | |
| JP2018522881A5 (enExample) | ||
| MX2012005497A (es) | Tivozanib y temsirolimus en combinacion. | |
| RU2021105387A (ru) | Способы и композиции для подавления пути egf/egfr в комбинации с ингибиторами киназы анапластической лимфомы | |
| WO2023056355A3 (en) | Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta | |
| ZA202201446B (en) | Methods of treating multifocal cancer | |
| RU2019108441A (ru) | Режим дозирования | |
| MX2023009024A (es) | Combinaciones terapeuticas de rosuvastatina y resmetirom para el tratamiento de trastornos hepaticos o trastornos lipidicos. |